Newer therapeutic modalities for Actinomycetoma by Nocardia species

Sardana, Kabir; Chugh, Shikha

doi:10.1111/ijd.14073

Cited by 7 publications

(10 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…By reducing the expenses and burden of hospital stay, it has a potential for better patient compliance too. 10 Irrespective of the treatment followed, the duration of the therapy always varies according to the clinical outcome which varies from an individual to another. In non-responders or those with allergies to the combination, TMP-SMX can be replaced by amoxicillin-clavulanate or carbapenems such as imipenem or meropenem and amikacin can be replaced by netilmicin.…”

Section: Treatment Of Mycetomamentioning

confidence: 99%

Clinical Features of Mycetoma and the Appropriate Treatment Options

Agarwal¹,

Jagati²,

Rathod³

et al. 2021

RRTM

View full text Add to dashboard Cite

Mycetoma is a chronic, suppurative and debilitating granulomatous infection seen mainly in tropical and subtropical areas and is now declared as a neglected tropical disease by the World Health Organization. The clinical diagnosis is usually characterized by a classical triad of localized swelling, underlying sinus tracts, and production of grains or granules, but unusual presentations are also seen. It is classified into eumycetoma caused by the fungus, and actinomycetoma caused by the bacteria. The clinical presentation of both is almost similar and a definite diagnosis is essential before starting the treatment as it differs for both. Surgical debulking followed by a prolonged course of medical therapy now forms the mainstay of treatment due to the long course of the disease and suboptimal response. This review focuses on the various usual as well as unusual clinical presentations of mycetoma, established treatment regimens as well as recent changes in the mode of administration of drugs and newer drugs for mycetoma.

show abstract

Section: Treatment Of Mycetomamentioning

confidence: 99%

Clinical Features of Mycetoma and the Appropriate Treatment Options

Agarwal¹,

Jagati²,

Rathod³

et al. 2021

RRTM

View full text Add to dashboard Cite

show abstract

“…Es importante resaltar que no se produjo óbito del paciente a pesar de su inmunosupresión considerando que es una enfermedad con alto índice de mortalidad debido al retraso en el diagnóstico (6) y tratamiento . La mortalidad se incrementa en pacientes que presentan inmunodeficiencia y en aquellos en los cuales se ven afectados más de dos órganos debido a diseminación de la infección.…”

Section: Discussionunclassified

Lymphocutaneous nocardiosis in an immunocompromised patient

Perez

Torreani

Kunzle

et al. 2020

Rev. virtual Soc. Parag. Med. Int

View full text Add to dashboard Cite

Se presenta el caso de un paciente, agricultor, adulto mayor, portador de hipertensión arterial, cardiopatía isquémica y cáncer de próstata con metástasis en hueso en tratamiento conservador. Acude por cuadro de 15 días de evolución con flictenas en miembro superior y fiebre. Durante su internación se aísla en la secreción de piel y es tratado con trimetoprin-Nocardia brasiliensis sulfametoxazol. En el 15° de internación se agrega una neumonía asociada a los cuidados de la salud. Posteriormente se detecta una lesión ósea destructiva en columna a nivel de L3. Sale de alta con el diagnóstico de nocardiosis linfocutánea en paciente inmunocomprometido a los 31 días de internación con buena respuesta clínica y con planes de continuar antibióticoterapia.

show abstract

“…We read with interest the case by Patra et al 1 and would like to highlight the dosing that we had used predating this case. 2 We would like to dwell on the laid down principles that dictate usage of antibiotics to effect clinical cure in actinomycotic mycetoma.…”

Section: Sirmentioning

confidence: 99%

“…In our cases, 2 we confirmed Nocardia by culture and used existing microbiological data gleaned from the prevalent worldwide data, using the laid down principles of therapy. We found the need to synergise the use of trimethoprim-sulfametoxazole (TMP/SMX) and linezolid as the existing data in this condition relied on at least two drugs.…”

Section: Sirmentioning

confidence: 99%

“…Our data showed that a regimen of linezolid 600 mg twice a day for three months along with TMP/ SMX (sulfamethoxazole 1200 mg and trimethoprim 240 mg) for six months led to remission in three out of four cases. 2 Mean time in which the lesion healed was three months. Previously, Welsch et al 3 and Epelboin et al 4 have also reported use of linezolid in the specific management of actinomycotic mycetoma.…”

Section: Sirmentioning

confidence: 99%

See 1 more Smart Citation